Fifth, other immunotherapies, such as camrelizumab, nivolumab, pembrolizumab, sintilimab and toripalimab, which had significant survival benefits for overall and PD-L1-positive advanced ESCC patients, were not included in this economic evaluation. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.